Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.40 |
| ▸ | HBB | P68871 | 1/20 | 0.40 |
| ▸ | PYGM | P11217 | 3/20 | 0.38 |
| ▸ | NT5E | P21589 | 1/20 | 0.36 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.36 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.36 |
| ▸ | TK2 | O00142 | 2/20 | 0.35 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.35 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5614068 | 0.86 | PYGM (0.50) | LMNASMN1; SMN2PYGMTK2ALOX12 | |
| SCHEMBL16042097 | 0.86 | TK1 (0.42) | LMNATK2ADRA1A | |
| SCHEMBL9545108 | 0.85 | TK2 (0.40) | LMNASMN1; SMN2PYGMTK2ALOX12 | |
| SCHEMBL6537910 | 0.84 | LMNA (0.46) | LMNASMN1; SMN2TSHRMAPTPMP22 | |
| SCHEMBL6885486 | 0.84 | LMNA (0.46) | LMNASMN1; SMN2TSHRMAPTPMP22 | |
| SCHEMBL22616910 | 0.83 | LMNA (0.37) | LMNASMN1; SMN2PYGMTK2ALOX12 | |
| SCHEMBL3978670 | 0.82 | PYGM (0.37) | LMNASMN1; SMN2TSHRPMP22PYGM | |
| SCHEMBL8951921 | 0.79 | RNASE1 (0.36) | LMNASMN1; SMN2PYGMTK2 | |
| SCHEMBL98410 | 0.78 | SLC28A1 (0.49) | P2RY6P2RY14 | |
| SCHEMBL28551951 | 0.78 | LMNA (0.51) | LMNASMN1; SMN2TSHRMAPTPMP22 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9861652-B2 | 2′ Fluoronucleosides | EMORY UNIVERSITY (US) | 2018-01-09 | — | — | US | disclosed |
| US-20160158266-A1 | 2' FLUORONUCLEOSIDES | EMORY UNIVERSITY | 2016-06-09 | — | — | US | disclosed |
| EP-2390257-A1 | 2'-fluoronucleosides | Emory University (US) | 2011-11-30 | — | — | EP | disclosed |
| US-20110256952-A1 | GOLF CLUB, SHAFT REPLACING METHOD AND HEAD REPLACING METHOD | BRIDGESTONE SPORTS CO., LTD. (JP) | 2011-10-20 | — | — | US | disclosed |
| US-6348587-B1 | PURINE OR PYRIMIDINE BASE DERIVATIVES; ANTICANCER, ANTITUMOR AND ANTIPROLIFERATIVE AGENTS; TREATING HIV AND HEPATITIS | EMORY UNIVERSITY | 2002-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160158266-A1 | 2' FLUORONUCLEOSIDES | PNP, BCL3, NPC1 | LMNA 2797/4885SMN1; SMN2 3514/4885TSHR 2699/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.